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Abstract
Background: The Cochrane risk of bias tool for randomized clinical trials was introduced in 2008 and has frequently
been commented on and used in systematic reviews. We wanted to evaluate the tool by reviewing published
comments on its strengths and challenges and by describing and analysing how the tool is applied to both Cochrane
and non-Cochrane systematic reviews.
Methods: A review of published comments (searches in PubMed, The Cochrane Methodology Register and Google
Scholar) and an observational study (100 Cochrane and 100 non-Cochrane reviews from 2014).
Results: Our review included 68 comments, 15 of which were categorised as major. The main strengths of the tool
were considered to be its aim (to assess trial conduct and not reporting), its developmental basis (wide consultation,
empirical and theoretical evidence) and its transparent procedures. The challenges of the tool were mainly considered
to be its choice of core bias domains (e.g. not involving funding/conflicts of interest) and issues to do with
implementation (i.e. modest inter-rater agreement) and terminology. Our observational study found that the tool was
used in all Cochrane reviews (100/100) and was the preferred tool in non-Cochrane reviews (31/100). Both types of
reviews frequently implemented the tool in non-recommended ways. Most Cochrane reviews planned to use risk of
bias assessments as basis for sensitivity analyses (70 %), but only a minority conducted such analyses (19 %) because, in
many cases, few trials were assessed as having “low” risk of bias for all standard domains (6 %). The judgement of at
least one risk of bias domain as “unclear” was found in 89 % of included randomized clinical trials (1103/1242).
Conclusions: The Cochrane tool has become the standard approach to assess risk of bias in randomized clinical trials
but is frequently implemented in a non-recommended way. Based on published comments and how it is applied in
practice in systematic reviews, the tool may be further improved by a revised structure and more focused guidance.
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Background
Since the early 1990s, the number of published syste-
matic reviews of randomized trials, both Cochrane and
non-Cochrane reviews, has steadily increased. The ideal
of taking a systematic approach to identify, summarise
and analyse comparable clinical trials as a basis for
therapeutic decisions has become more widespread, and
systematic reviews have had a huge impact on clinical
research and practice.
However, one obstacle to the usefulness of a syste-
matic review is the possibility that some of the included
trials are biased due to flaws in their design, conduct,
analysis or reporting. A meta-analysis of biased effect es-
timates will likely produce a biased pooled analysis with
increased precision and greater credibility. Thus, for au-
thors of a systematic review, it is paramount to adequately
address the risk of bias in the included trials [1].
For this purpose, the Cochrane tool for assessing risk
of bias in randomized clinical trials (i.e. the tool) was
released in 2008 and updated in 2011. The tool is based
on seven bias domains: sequence generation and alloca-
tion concealment (both within the domain of selection
bias or allocation bias), blinding of participants and
personnel (performance bias), blinding of outcome as-
sessors (detection bias), incomplete outcome data (attri-
tion bias), selective reporting (reporting bias) and an
auxiliary domain: “other bias.” For each bias domain, the
tool urges users to assign a judgement of “high,” “low”
or “unclear” risk of bias and to document the basis for
their judgements (e.g. with verbatim quotes). The bias
domains of the tool were selected with the intention to
cover all fundamental bias mechanisms in randomized
trials [2].
Several years have passed since the release of the first
version of the tool. Over this period, the tool has been
used in numerous systematic reviews, the scientific
debate on risk of bias has proceeded (for example,
reflecting on the role of source of funding [3–6] or
other “meta-biases” [7]) and research publications have
analysed user experience [8] and inter-agreement rates
[9–11]. Additionally, a complementary tool for assessing
non-randomized trials has been developed [12].
Researchers from the original development team and
members of the Cochrane Bias Methods Group are
planning a revision of the tool. To evaluate the tool and
to provide a better basis for the revision, we intended (1)
to identify, summarise and analyse published comments
on the strengths and challenges of the tool and (2) to
describe and analyse how the tool is used in both
Cochrane and non-Cochrane reviews.
Methods
This study involved a review of published comments on
the Cochrane tool for assessing risk of bias in randomized
clinical trials and an observational study of how the tool is
used in systematic reviews (please refer to Additional file 1
for the study’s PRISMA checklist).
Review of published comments
We sought publications that explicitly commented on
the tool. We defined “major comments” as longer com-
ments with a substantial reflection (typically ≥100 words
of text) on the strengths or weaknesses of the tool, for
example, in the form of an editorial. We also included
“minor comments,” which we defined as shorter com-
ments without a substantial reflection (typically <100
words of text) on the strengths or weaknesses of the
tool, for example, in the form of minor elements of a
discussion in a publication. We excluded “peripheral re-
marks” on the tool, which we defined as remarks that
were implicit or short and tangential. If an author had
several publications included with similar comment
contents, only the publication with the most detailed
comment was considered major.
We searched PubMed, The Cochrane Methodology
Register and Google Scholar for publications from the
start of 2008 to the end of 2014. No language restriction
was applied, and Google Translate was used for non-
familiar languages. The search strategy was developed
iteratively (see Additional file 2).
One author (LJ) decided on inclusion of publications
and categorised them as “major comments” and “minor
comments” (and “peripheral remarks”). A second author
(AS) checked the categorisation. Two authors (LJ and
AS) extracted data independently. Any disagreements
were solved by discussion and by consulting a third
author (DL or AH).
The following information was extracted: publication
year, publication type, tool version considered (i.e. 2008
or 2011) and the exact wording of the comment.
Comments from the included publications were cate-
gorised according to whether they expressed “strengths,”
“challenges” or “suggestions” and summarised into
broader themes (each addressing a similar type of topic).
We noted the numerical distribution of comparable
comments, but our main intention was a qualitative
mapping of the themes addressed and a categorisation
according to whether they addressed a core design
feature of the tool or an issue related to implementation.
Observational study of how the tool is used in systematic
reviews
One author (DL) identified 100 Cochrane reviews (or
Cochrane review updates) from PubMed in reverse
chronological order from 31.12.2014 until 20.11.2014
(see Additional file 2). The same author manually identi-
fied 100 non-Cochrane reviews from PubMed in reverse
chronological order from 31.12.2014 until 22.12.2014.
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A second author (AS) checked the inclusion. We de-
fined a non-Cochrane review as a self-declared sys-
tematic review with at least one included randomized
clinical trial. We excluded any non-Cochrane review
that was also published as a Cochrane review.
Three authors (AS, DL and LJ) extracted data inde-
pendently: intervention type (pharmacological or non-
pharmacological); inclusion of meta-analyses; number of
trials and how many trials were categorised as “high,”
“unclear” and “low” risk of bias; the method used for
judging risk of bias (or quality) and how it was imple-
mented; the type and frequency of both standard and
non-standard domain use; the use of merging or split-
ting of standard domains (e.g. merging blinding domains
or splitting for different outcomes); the use of the “other
bias” domain; how risk of bias assessments were incor-
porated into statistical analysis using sensitivity analyses;
whether risk of bias judgements were explicitly men-
tioned in the abstract, discussion or conclusion; and
whether The Grading of Recommendations Assessment,
Development and Evaluation (short GRADE) had been
incorporated. We compared differences in proportions
between Cochrane and non-Cochrane reviews using
Fisher’s exact test. In cases where Cochrane or non-
Cochrane reviews included both randomized clinical
trials and non-randomized clinical trials, we disregarded
the non-randomized trials.
Results
Review of published comments
We read 976 full text publications of which we excluded
908 (Fig. 1). Thus, we included 68 publications, of which
we categorised 15 as “major comments” and 53 as
“minor comments” (Tables 1 and 2).
The strengths of the tool were addressed in five “major
comments” relating to three themes: aims, developmen-
tal basis and transparency. The comments praised the
tool for aiming to assess conduct (and not reporting),
being based on theoretical and empirical evidence and
on broad consultation and facilitating transparent assess-
ment of bias.
The challenges of the tool were addressed in 15 “major
comments” relating to four themes: choice of the core
bias domains, implementation, overall risk of bias and
special situations. The comments on choice of core bias
domains expressed concern whether the chosen domains
comprehensively address all threats to validity (for ex-
ample, five comments reflected on including funding as
an independent bias domain). Comments on implemen-
tation pointed to difficulties in the subjective
Fig. 1 Flowchart of the inclusion of comments on the Cochrane risk of bias tool for randomized clinical trials—evaluation of the Cochrane tool
for assessing risk of bias in randomized clinical trials. 1N= the number of records/comments screened for inclusion. 2Of the 976 full-texts assessed,
793 full-texts did not comment on the Cochrane risk of bias tool for randomized clinical trials (i.e. the tool). 3Seven records (ordered through The
Royal Danish Library) were not retrievable and therefore not assessed. 4183 publications were independently assessed by two authors to check
type, categorisation and commentary. 5Major comments were defined as longer comments with a substantial reflection (typically ≥100 words of
text) on the strengths or challenges of the tool. 6Minor comments were defined as shorter comments without a substantial reflection (typically
<100 words of text) on the strengths or challenges of the tool. 7Peripheral remarks (defined as implicit or short and tangential) were excluded
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interpretation of the tool and expressed concerns about
modest inter-observer agreement, difficulty in assessing
selective reporting of outcomes, terminological ambigu-
ity (i.e. of the terms subjective/objective) and the low
proportion of reviews using risk of bias assessments as a
basis for sensitivity analyses. The comments on overall
risk of bias expressed concern about the challenges in
assigning an overall risk of bias to a trial based on risk
of bias of single domains to the trial as such. A single
comment regarded the special situation where the tool
was used to assess risk of bias based on clinical study re-
ports (and not clinical trial publications).
Specific suggestions to improve the tool were included
in nine “major comments” relating to three themes: im-
proved guidelines, further research and the inclusion of
funding as a bias domain. The comments on guidelines
suggested that updated and improved guidance and
more training options for users were needed. The com-
ments on research suggested further methodological re-
search (for example, blind versus non-blind risk of bias
assessments). The comments on funding suggested that
funding/conflicts of interest should be incorporated into
the tool as a specific bias domain.
All themes addressed in the “major comments” were
represented in the “minor comments” (see Additional
file 2). Additional themes addressed only in the “minor
comments” included graphical representation, external
validity and non-randomized designs. Specifically, (i) one
comment praised the tool for its graphical representa-
tion of risk of bias assessments, (ii) one comment criti-
cised that the tool does not address external validity
(and only focuses on internal validity) and (iii) one com-
ment noted that non-randomized trials should be in-
cluded in Cochrane reviews and should be addressed in
risk of bias assessments. The latter two suggestions are
inconsistent with the aim of the tool, which is to assess
only bias (i.e. internal validity) in randomized clinical tri-
als. Such comments help to unveil the assumptions and
basic structure of the tool but would be difficult to
implement without significantly changing the tool.
Other comments reflected concerns about the imple-
mentation of the tool. An example is the suggestion for
improved guidelines for how to assess selective outcome
reporting. Also, improved training options and more
detailed guidelines aimed to improve agreement rates
address the implementation of the tool. Such suggestions
are easier to implement while keeping the fundamental
structure of the tool intact.
Analysis of user patterns in systematic reviews
All Cochrane reviews assessed risk of bias using the
Cochrane risk of bias tool (100/100, 100 %) (Tables 3
and 4). Most of the non-Cochrane reviews assessed risk
of bias (80/100, 80 %), with the Cochrane tool being the
most frequently used (31/80, 39 %). Other tools and
scales used to assess risk of bias included the Jadad
Quality Assessment Scale (19/80, 24 %) [13] and the
Physiotherapy Evidence Database (short PEDro) scale
(5/80, 6 %) [14] (Table 4).
The majority of Cochrane reviews included one or
more meta-analyses (85/100, 85 %). According to the in-
formation reported in their methods section, most of the
Cochrane reviews had planned to perform sensitivity
analyses based on risk of bias (70/100, 70 %). One fifth
of the Cochrane reviews reported to have performed
sensitivity analyses (19/100, 19 %). Few reviews based
sensitivity analyses on an overall risk of bias (2/19,
11 %). Most reviews based sensitivity analyses on indi-
vidual bias domains (9/19, 47 %) or did not state what
sensitivity analyses were based on (8/19, 42 %). The ma-
jority of the Cochrane reviews who did not conduct the
planned analyses reported that the lack thereof was due
to insufficient data (41/50, 82 %), either because there
were few trials included in the review or few trials with
“low” risk of bias. The remaining reviews did not explain
why they did not perform the planned analyses (9/50,
18 %) (Tables 3 and 4).
Table 1 Characteristics of published comments on the Cochrane
risk of bias tool for randomized clinical trials—evaluation of the
Cochrane tool for assessing risk of bias in randomized clinical trials
Publication characteristics Number of comments: 68 (100 %)
Publication category
Majora 15 (22 %)
Minorb 53 (78 %)
Publication type
Comment/editorial/letterc 6 (9 %)
Survey/qualitative case study 33 (49 %)
Experimental/observational study 23 (33 %)
Other 6 (9 %)
Tool version considered/applied
2011 54 (79 %)
2008 6 (9 %)
Not specified 8 (12 %)
Year of publication
2008–2010 9 (13 %)
2011 10 (15 %)
2012 8 (12 %)
2013 14 (20 %)
2014 27 (40 %)
aMajor comments were defined as longer comments with a substantial
reflection (typically ≥100 words of text) on the strengths or challenges of the
Cochrane risk of bias tool for randomized clinical trials (i.e. the tool)
bMinor comments were defined as shorter comments without a substantial
reflection (typically ≤100 words of text) on the strengths or challenges of the tool.
cComments, editorials and letters (to the editor) were defined as such
if self-declared
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Table 2 Selected key points of major comments on the Cochrane risk of bias tool for randomized clinical trials: strengths,
challenges and suggestions
First authora Category Theme Key point
Armijo-Olivo Strengths None mentioned
Challenges • Implementation (1.)
• Overall risk of bias (2.)
• Bias domains (3.)
1. “…the large number of trials classified as high or unclear RoB
[risk of bias] casts doubts about the discrimination power of the RoB
[risk of bias] tool to […] explain variability of treatments effects
across studies…”
2. “…the overall assessment of the RoB [risk of bias] may not be useful
to determine quality of individual trials.”
3. “…other methodological factors could be important for evaluating
RoB and could be considered for inclusion in the RoB [risk of bias]
tool after careful empirical evidence testing.”
Suggestions • Guidelines (1.) 1. “Improved guidelines to apply the RoB [risk of bias] tool and revisions
to the tool for different health areas are needed.”
Bero Strengths None mentioned
Challenges • Bias domains (1.) 1. “The current Cochrane risk of bias tool is insufficient to assess bias
related to study funding sources.”
Suggestions • Funding (1.) 1. “…the Cochrane risk of bias tool should include funding source as a
standard item because: 1. Funding source fits the definition of bias, 2. There
is empirically-based evidence of bias related to funding source, 3. The observed
bias related to funding source cannot be captured by the risk of bias criteria
currently assessed with the risk of bias tool, 4. Risks of bias are not mutually
exclusive, 5. Bias may be related to funding source even when all studies
are industry-funded.”
Boutron Strengths • Aims (1. 2.)
• Improvement (3.)
• Transparency (1.)
1. “…the tool aims at being completely transparent, with a separation of
the facts and reviewers’ judgments. This aim is particularly important
because reviewers, editors, and readers can challenge the author on
the judgment.”
2. “…the tool is intended to assess the risk of bias related to the design,
conduct, and analyses of the trial and not the quality of reporting.”
3. “This tool has been an important step forward in the assessment of
the risk of bias in systematic reviews and meta-analyses.”
Challenges None mentioned
Suggestions None mentioned
De Bruin Strengths None mentioned
Challenges • Implementation (1.) 1. “…many do assess methodological quality, but very few incorporate them
[/risk of bias assessments] in their analyses.”
Suggestions • Guidelines (1.) 1. “…systematic reviewers could consider adapting the risk-of-bias tool to
the literature…”
Hartling Strengths None mentioned
Challenges • Implementation (1.)
• Overall risk of bias (2.)
• Special situations (3.)
1. “Low agreement between reviewers suggests the need for more specific
guidance regarding interpretation and application of the Risk of Bias (ROB) tool…”
2. “The majority of trials in the sample were assessed as high or unclear risk
of bias…This raises concerns about the ability of the ROB [risk of bias] tool
to detect differences across trials that may relate to biases in estimates of
treatment effects.”
3. “…trials with different design features (e.g., crossover) or hypotheses
(e.g., equivalence, non-inferiority), and those examining non-pharmacological
interventions appear to create more ambiguity for risk of bias assessments.”
Suggestions • Guidelines (1.) 1. “There is a need for more detailed guidelines to apply […] the ROB
[risk of bias] tool and […] further testing with the modified tool is warranted.”
Hróbjartsson Strengths • Aims (1.)
• Background (1.)
1. “The risk of bias tool provides a standardised approach, based on items
selected on both theoretical and empirical grounds, and following broad
consultations with clinical research methodologists.”
Challenges • Bias domains (2.)
• Implementation (1.)
1. “The risk of bias tool is a comparatively recent development that still
likely needs refinement.”
2. “It is not clear that the risk of bias tool in its present version addresses
this problem [of funding] adequately.”
Suggestions None mentioned
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Table 2 Selected key points of major comments on the Cochrane risk of bias tool for randomized clinical trials: strengths,
challenges and suggestions (Continued)
Ivers Strengths None mentioned
Challenges • Bias domains (1.)
• Implementation (2.)
• Overall risk of bias (3.)
1. “The risk of bias tool does not capture all sources of methodological bias
and poor reporting interferes with the assessment of many domains.”
2. “While the overall risk of bias assessment using the Cochrane Risk of Bias
Tool has been shown to differentiate effect sizes (i.e. higher risk of bias studies
usually have larger effect sizes), 10 studies at high risk of bias may still offer
valuable knowledge…”
3. “…assigning trials with high risk of bias in a single domain a status of high
risk of bias overall may be arguable.”
Suggestions None mentioned
Jefferson Strengths • Aims (1.) 1. “The real strength of the risk of bias tool appears not to be in the final
judgements it enables, but rather in the process it helps facilitate: critical
assessment of a clinical trial.”
Challenges • Bias domains (1. 3.)
• Implementation (2.)
1. “The current Cochrane risk of bias tool is not adequate for the task as it
does not reliably identify all types of important biases, and nor does it organise
and check the coherence
of large amounts of information.”
2. “We found the Cochrane risk of bias tool to be difficult to apply to clinical
study reports…[since]…its use lends itself to a checklist approach (in which
each design item is sought and, if found, eliminated from the bias equation
rather than with thought and consideration).”
3. “Many of the variables we found to be important when assessing the trial
(e.g. date of trial protocol, date of un-blinding, date of participant enrolment)
are simply not captured in the risk of bias tool…”
Suggestions None mentioned
Katikireddi Strengths None mentioned
Challenges • Implementation (1.) 1. “…reviewers are struggling to understand and/or operationalize current
guidance on how to conduct and incorporate critical appraisal [/risk of bias]
within synthesis.”
Suggestions • Guidelines (1.)
• Research (1.)
1. “Further research is required to establish the relative importance of different
forms of bias and their likely impact […] and also to clarify how critical
appraisals should be incorporated into SR [systematic review] findings.”
Morissette Strengths • Aims (1.) 1. “The Cochrane 'Risk of bias' tool differs from other quality appraisal tools
because it questions the degree to which a study’s results should be believed…”
Challenges • Implementation (1.) 1. “The results of our review provide no clear guidance as to whether risk of
bias assessments should be completed in a blind or un-blind manner.”
Suggestions • Research (1.) 1. “…we encourage further research in this area [of blind vs. un-blind risk of
bias assessment] and recommend using all of the important components of
the Cochrane 'Risk of bias' tool.”
Moustgaard Strengths None mentioned
Challenges • Implementation (1.) 1. “No characterization of subjective vs. objective outcomes relevant to risk of
performance bias is given explicitly in the Cochrane Handbook nor did we find
it in the methodological articles or the clinical trial reports we reviewed.”
Suggestions None mentioned
Roseman Strengths None mentioned
Challenges • Bias domains (1.) 1. “…inclusion of risk of bias from conflicts of interest could reflect mechanisms
through which industry involvement can influence study outcomes that are
not fully captured by the current domains of the risk of bias tool.”
Suggestions • Funding (1.) 1. “…we recommend that the Cochrane Collaboration reconsider its position
that trial funding and trial author-industry financial ties not be included in the
risk of bias assessment.”
Savović Strengths • Aims (3.)
• Background (1.)
• Transparency (2.)
1. “…[the tool has] a standardized approach to bias assessments…”
2. “…[the tool has] transparency provided by requesting quotes…”
3. “…[the tool provides] a platform to encourage critical thinking.”
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One tenth of the non-Cochrane reviews that had any
risk of bias assessment reported plans for sensitivity
analyses based on risk of bias assessments (8/80, 10 %).
One in seven of all the non-Cochrane reviews reported
to have performed sensitivity analyses based on risk of
bias or quality assessments (11/80, 14 %). In nine reviews,
the sensitivity analyses were based on an overall risk of
bias (9/11, 82 %) (Table 4).
Two Cochrane reviews performed subgroup analyses
(both with “low” versus “high” risk of bias) (2/100, 2 %).
None of the non-Cochrane reviews performed subgroup
analyses based on risk of bias.
Most Cochrane reviews explicitly commented on risk
of bias assessments in the discussion and/or conclusion
(89/100, 89 %), although fewer incorporated this infor-
mation into the abstract (80/100, 80 %). Most of the
non-Cochrane reviews that applied the Cochrane tool
and some of the non-Cochrane reviews that applied
non-Cochrane tools explicitly commented on risk of
bias assessments in the discussion and/or conclusion
(Cochrane tool: 25/31, 81 %; non-Cochrane tools: 12/
49, 24 %) and more than half incorporated this infor-
mation into the abstract (Cochrane tool: 18/31, 58 %;
non-Cochrane tools: 30/49, 61 %). No significant
differences were found between the non-Cochrane re-
views that used the Cochrane tool versus the non-
Cochrane reviews that used other risk of bias tools
when comparing the use of risk of bias results in the
abstract and discussion/conclusion.
The majority of Cochrane reviews (64/100, 64 %) and
few non-Cochrane reviews (4/80, 5 %) incorporated
GRADE in their overall assessment of confidence in the
results (Table 4).
The majority of Cochrane reviews applied all standard
domains (59/100, 59 %). Only few Cochrane reviews
explicitly assessed risk of bias on an outcome level (i.e.
differentiating between subjective versus objective out-
comes) (12/100, 12 %). Most Cochrane reviews (88/100,
88 %) performed one risk of bias assessment without
making it clear whether this assessment concerned a sin-
gle outcome, a group of outcomes or the trial as a whole.
A similar pattern was seen for non-Cochrane reviews
(Table 5).
One third of the Cochrane reviews merged standard
bias domains (37/100, 37 %), most often merging “per-
formance bias” and “detection bias” into a single blind-
ing bias domain (31/37, 84 %) (predominantly done in
updates of reviews that had originally used the 2008
Table 2 Selected key points of major comments on the Cochrane risk of bias tool for randomized clinical trials: strengths,
challenges and suggestions (Continued)
Challenges • Bias domains (1.)
• Implementation (2.)
1. “Some of the items that authors have included (such as sample size
calculations and funding source) are explicitly discouraged in the
Cochrane Handbook guidance. While there is evidence that some factors
are empirically associated with effect estimates, such as single versus
multicentre design, early stopping of trials and funding source [14-16],
the extent to which these should be considered alongside the main bias
domains is still a topic of debate.”
2. “The main purpose of this evaluation was to identify potential
problems with the RoB [risk of bias] that can be rectified, and we suspect
that users who encountered problems are more likely to have responded.
This speculation is based on the high proportion of respondents who
reported having problems with some aspects of the RoB tool, especially
with individual RoB domains.”
Suggestions • Guidelines (1.) 1. “It is important that guidance and training materials continue to be
developed for all aspects of the tool…”
Sterne Strengths None mentioned
Challenges • Bias domains (1.) 1. “The current RoB [risk of bias] tool does not work well for assessment of
selective reporting.”
Suggestions • Funding (1.) 1. “…the Cochrane risk of bias tool should not include funding source as a
standard item.”
Vale Strengths None mentioned
Challenges • Implementation (1. 2.)
• Bias domains (2.)
1. “The Cochrane Handbook states that because the ability to measure the
true bias (or even the true risk of bias) is limited, then the possibility to
validate a tool to assess that risk is also limited. Nevertheless, authors of
Cochrane systematic reviews are required to use the Cochrane risk of bias tool.”
2. “Assessing risk of bias was particularly difficult for the more subjective
domains [i.e. ‘selective outcome reporting’ and ‘other bias’].”
Suggestions None mentioned
Major comments were defined as longer comments with a substantial reflection (typically ≥100 words of text) on the strengths or challenges of the Cochrane risk
of bias tool for randomized clinical trials (i.e. the tool)
aSee Additional file 2 for references
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version of the tool in which the domains were merged
(21/31, 68 %)). Approximately one fifth of the Cochrane
reviews split a standard bias domain into separate sub-
entities (18/100, 18 %), for example, blinding (within the
performance bias domain) was split into blinding of
personnel and blinding of patients or incomplete out-
come data (i.e. attrition bias) was split into assessment
of intention-to-treat and assessment of dropouts. Again,
a similar pattern was seen for non-Cochrane reviews
(Table 5).
A minority of Cochrane reviews added non-standard
bias domains to the tool (11/100, 11 %). “Baseline imbal-
ance” (6/11, 55 %) and “funding/conflicts of interest” (5/
11, 45 %) were the most used. A similar pattern was
found for non-Cochrane reviews (Table 6). The majority
of Cochrane reviews used the “other bias” domain op-
tion for the same purpose (73/100, 73 %). “Baseline im-
balance” (33/73, 45 %) and “funding/conflicts of interest”
(23/73, 32 %) were also the most used “other biases.”
Most non-Cochrane reviews that used the Cochrane tool
included the “other bias” domain (17/31, 55 %), but none
of the non-Cochrane reviews reported what specific
items were considered as “other biases” (Table 6).
Very few of the randomized clinical trials included in
the Cochrane reviews had all standard domains judged
as “low” risk of bias (74 of 1242 trials, 6 %). Most had at
least one standard domain judged as “unclear” risk of
bias (407 of 1242 trials, 33 %) or as “high” risk of bias
(761 of 1242 trials, 61 %). A similar pattern was found
for the non-Cochrane reviews (Table 3).
Thus, only a few reviews could conduct sensitivity
analyses based on overall risk of bias, e.g. the Cochrane
reviews with at least one trial with all standard domains
judged as “low” risk of bias and at least one trial with
one bias domain judged as “high” risk of bias (26/100,
26 %) (or as “high”/“unclear” risk of bias (32/100, 32 %)).
A similar pattern was found for the non-Cochrane
reviews (Table 3).
Discussion
Published comments about the Cochrane risk of bias
tool considered it to be an important step forward but
Table 3 Characteristics of included Cochrane and non-Cochrane reviews—evaluation of the Cochrane tool for assessing risk of bias
in randomized clinical trials
Publication characteristics 100 Cochrane reviews (100 %) 100 non-Cochrane reviews (100 %) P value*
Intervention
Pharmacologic 55 (55 %) 29 (29 %) 0.020
Non-pharmacologic 45 (45 %) 71 (71 %) 0.061
Review has ≥1 meta-analysis
Yes 85 (85 %) 45 (45 %) 0.0065
Included trials
Number of randomized clinical trials in total 1242 1249
-Lowa risk of bias 74 (6 %) 25 of 424e (6 %) 1.00
-Unclearb risk of bias 407 (33 %) 226 of 424e (53 %) 0.0001
-Highc risk of bias 761 (61 %) 173 of 424e (41 %) 0.0001
Reviews with ≥1 low risk of bias trial and ≥1 high risk of bias trial 26 (26 %) 6 of 18f (33 %) 0.60
Reviews with ≥1 low risk of bias trial and ≥1 high or unclear
risk of bias trial
32 (32 %) 8 of 18f (44 %) 0.47
Number of randomized clinical trials includedd in a review
-One to five 39 (39 %) 38 (38 %) 1.00
-Six to ten 23 (23 %) 26 (26 %) 0.75
->Ten 38 (38 %) 36 (36 %) 0.89
*P values were calculated with Fisher’s two-tailed exact test
aIf a trial had all standard domains (not including the “other bias” domain) judged as “low” risk of bias, we defined the trial as “low risk of bias”
bIf a trial had at least one of the standard domains (not including the “other bias” domain) judged as “unclear” risk of bias and no domains judged as “high” risk
of bias, we defined the trial as “unclear risk of bias.” The judgement of at least one standard risk of bias domain (not including the “other bias” domain) as
“unclear” was found in 1103 of 1242 included randomized clinical trials (89 %)
cIf a trial had at least one of the six standard domains (not including the “other bias” domain) judged as “high” risk of bias, we defined the trial as “high risk of bias”
dWe only included systematic reviews with one or more randomized clinical trials included in their analyses
eIt was only possible to assess whether a trial was judged as “low,” “unclear” or “high” risk of bias in 18 non-Cochrane reviews (which provided information on risk
of bias judgements for all six standard domains (not including the “other bias” domain) for individual trials via a “risk of bias graph/summary” or “characteristics of
studies” section)
fThe 18 non-Cochrane reviews included 424 randomized clinical trials in total
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highlighted some challenges including its omission of
funding/conflicts of interest and its modest inter-
agreement rates. Suggestions for improvement included
more explicit guidelines and training options. The tool
was used in 100 % of Cochrane reviews and in 31 % of
non-Cochrane reviews in a sample published towards
the end of 2014. Often the tool was implemented in a
non-recommended way. Also, 70 % of Cochrane reviews
planned to use the risk of bias assessment as basis for
sensitivity analyses, but only 19 % of Cochrane reviews
conducted such analyses, in many cases, because there
were few trials with “low” risk of bias.
Strengths and weaknesses
We are not aware of other reviews of published com-
ments on the Cochrane risk of bias tool. Our study
complements previous studies of user experience [8]
and inter-observer variance [9–11].
It is challenging to search for published comments as
not all are indexed in standard databases. However, we
focused on “major comments,” which are more reliably
identified. It is reasonable to assume that the threshold
for publishing a comment pointing out a problem with
the tool (and maybe suggesting an improvement) is
lower than for publishing a comment praising the tool.
Thus, we consider the qualitative summary of the
expressed themes as more interesting than the quantita-
tive distribution of the themes. The analyses of how the
tool was used were based on samples of representative
and contemporary Cochrane and non-Cochrane reviews,
enabling both a description and comparison between the
two types of reviews.
Table 4 User patterns of risk of bias implementations in Cochrane and non-Cochrane reviews—evaluation of the Cochrane tool for
assessing risk of bias in randomized clinical trials
Risk of bias implementation 100 Cochrane reviews (100 %) 100 non-Cochrane reviews (100 %) P value*
Risk of bias assessment in reviews
Any risk of bias (or quality) assessment 100 (100 %) 80 (80 %) 0.30
Cochrane risk of bias tool 100 (100 %) 31 of 80 (39 %) 0.0002
Jadad scale 0 (0 %) 19 of 80 (24 %) 0.0001
PEDro scale 0 (0 %) 5 of 80 (6 %) 0.019
Own construct or other scale 0 (0 %) 25 of 80 (31 %)c 0.0001
Descriptive use of risk of bias assessment
Explicit mentions risk of bias in abstract 80 (80 %) 18 of 31d (58 %) 0.42
Explicit mentions risk of bias in discussion/conclusion 89 (89 %) 25 of 31d (81 %) 0.76
Explicit mentions risk of bias in both abstract and discussion/conclusion 73 (73 %) 15 of 31d (48 %) 0.31
Sensitivity and subgroup analyses based on risk of bias
Review planned (in methods) to do sensitivity analyses 70 (70 %) 8 of 80 (10 %) 0.0001
Review performed sensitivity analyses 19 (19 %) 11 of 80 (14 %) 0.55
Based on overall risk of bias 2 of 19 (11 %) 9 of 11 (82 %) 0.015
Based on individual risk of bias domains 9 of 19 (47 %) 2 of 11 (18 %) 0.45
Unclear what analyses were based on 8 of 19 (42 %) 0 of 11 (0 %) 0.077
Review performed, but did not plan sensitivity analyses 1 of 19 (5 %) 8 of 11 (72 %) 0.0084
Review performed subgroup analysesa 2 (2 %) 0 of 80 (0 %) 0.50
Review planned, but did not perform analyses 50 of 70 (71 %) 5 of 8 0.52
Due to insufficient datab 41 of 50 (82 %) 3 of 5 0.73
No explanation provided 9 of 50 (18 %) 2 of 5 0.33
GRADE
Review incorporated GRADE 64 (64 %) 4 of 80 (5 %) 0.0001
*P values were calculated with Fisher’s two-tailed exact test
aAll subgroup analyses were based on “low” versus “high” risk of bias
b“Insufficient data” was due to few trials included in the review or few trials judged as “low risk of bias”
c15 non-Cochrane reviews made their own risk of bias construct/tool, eight incorporated two constructs/tools and the following constructs/tools (/methods) were
used 18 times in total: CASP (×2), CEBM, Chalmers, CONSORT (×2), CTAM, Downs and Black criteria (×2), Evidence-based medicine toolkit, GRADE (×2), Methods
Guide for Effectiveness and Comparative Effectiveness Reviews, MOOSE (×2), Newcastle Ottawa, QUOROM and STROBE
d31 of 100 non-Cochrane reviews used the Cochrane risk of bias tool for randomized clinical trials (i.e. the tool) and were compared to the 100 Cochrane reviews
that used the tool for randomized clinical trials
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Other similar studies
Based on feedback from focus groups and an online
survey, Savović and colleagues concluded that users of
the Cochrane tool identified positive experiences and
perceptions of the tool and that revisions and associated
guidance as well as improved provision of training may
improve implementation [8]. Several studies have ana-
lysed the assessment of risk of bias in systematic reviews
[10–15]. Hartling and colleagues and Armijo-Olivo and
colleagues concluded unsatisfactory agreement rates by
users of the tool and suggested the need for more de-
tailed guidance in assessing the risk of bias [9, 15]. Com-
ments made by the authors of all three studies are
included in our study.
Hopewell and colleagues [16] studied assessment of
risk of bias in Cochrane and non-Cochrane reviews
indexed in The Database of Abstracts of Reviews of Ef-
fects (DARE) [17] and published in 2012. They reported
that all reviews incorporated some kind of assessment of
risk of bias, even though Cochrane reviews more often
specified which tool was used. Also, the Cochrane tool
was used more often in Cochrane reviews (and the Jadad
scale was used less often). A low proportion of reviews
incorporated sensitivity analyses based on risk of bias in
their conclusion.
Our study confirms and expands on the findings of
Hopewell and colleagues. We found that all 100
Cochrane reviews in our sample used the Cochrane risk
of bias tool, but that only one in five Cochrane reviews
conducted sensitivity analyses based on risk of bias as-
sessments, despite the fact that seven in ten had planned
to do so.
Mechanisms and implications
Based on the degree of implementation, the tool has
proven successful. All Cochrane reviews and a fair
proportion of non-Cochrane reviews used the tool in
2014. However, the tool is often used in ways not
recommended.
Firstly, both Cochrane and non-Cochrane reviews im-
plemented non-standard domains, either as fully new
domains or incorporated into the “other bias” function.
Approximately one in six Cochrane reviews added
“intervention differed between groups” under “other
Table 5 Use of risk of bias and risk of bias domains in the Cochrane and non-Cochrane reviews that applied the Cochrane risk of
bias tool for randomized clinical trials
Use of risk of bias and risk of bias domains 100 Cochrane reviews (100 %) 31 non-Cochrane reviews (100 %)f P value*
Use of risk of bias
Summarises risk of bias on an outcome levela 12 (12 %) 2 (6 %) 0.73
Unclear what level risk of bias was summarised onb 88 (88 %) 29 (94 %) 0.88
Use of risk of bias standardc domains
Review uses the 2011 tool version 100 (100 %) 26 (84 %) 0.65
Review uses all standardc domains 59 (59 %) 16 (52 %) 0.73
-Sequence generation 100 (100 %) 30 (97 %) 1.00
-Allocation concealment 100 (100 %) 30 (97 %) 1.00
-Blinding of patients and care providers 62 (62 %) 21 (68 %) 0.87
-Blinding of outcome assessors 65 (65 %) 20 (65 %) 1.00
-Incomplete outcome data 99 (99 %) 29 (94 %) 0.88
-Selective reporting 87 (87 %) 25 (81 %) 0.88
Merging and splitting of standardc domains
Review merges two standardc domains 37 (37 %) 8 (26 %) 0.53
-Merges risk of bias domains on an outcome leveld 6 of 37 (16 %) 0 of 8 (0 %) 0.57
-Does not merge risk of bias domains on an outcome level 31 of 37 (84 %) 8 of 8 (100 %) 0.79
Review splits a standardc domain into two or more domainse 18 (18 %) 7 (23 %) 0.62
*P values were calculated with Fisher’s two-tailed exact test
aOne or more domains were separately assessed for more than one outcome or groups of outcomes (i.e. subjective versus objective outcomes)
bReview has a singular risk of bias assessment despite more than one outcome included in the review. No review based its risk of bias assessment on a singular
or primary outcome
cThe six standard domains (not including the “other bias” domain) included in the Cochrane risk of bias tool for randomized clinical trials (i.e. the tool)
di.e. merges blinding of patients and care providers with blinding of outcome assessors into one blinding domain and evaluates blinding for subjective/objective
or explicit (≥2) outcomes.
ei.e. splits blinding of patients and care providers into blinding of personnel and blinding of patients or splits incomplete outcome data into assessment of
intention-to-treat and assessment of dropouts.
f31 of 100 non-Cochrane reviews used the Cochrane risk of bias tool for randomized clinical trials (i.e. the tool) and were compared to the 100 Cochrane reviews
that used the tool for randomized clinical trials
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bias,” though this problem is intended to be addressed
under “performance bias.” Furthermore, a similar pro-
portion of Cochrane reviews added “unclear reporting”
under “other bias,” although the tool specifically ad-
dresses conduct and not reporting (unclear reporting
would normally result in contacting trial authors for
clarification). Thus, there seems to be a widespread un-
certainty as to the scope of what the tool seeks to evalu-
ate. Adding bias domains and using the “other bias”
option are primarily intended for special situations, for
example, when assessing crossover trials. Thus, better
guidance as to what is meant by “bias,” “bias domain”
and the basic purpose of the tool is warranted.
Secondly, only a minority of reviews used the risk of
bias assessments as a basis for sensitivity analyses. This
problem seems to be a result of few trials having a “low”
risk of bias, although sensitivity analyses may be based
on “unclear” versus “high” risk of bias. Only 6 % of the
trials included in our review sample had been classified
as “low” risk of bias for all domains. It is unclear
whether such a low proportion (also found by e.g. Har-
tling and colleagues [9] and Hopewell and colleagues
[16]) is a fair reflection of the “true” risk of bias in trials
or whether the tool as currently applied is too sensitive
(or authors simply do not use all sources of information
as recommended and possibly opt for “unclear” based
on the published report). A better guideline on how to
move from the level of individual bias domains to an
overall risk of bias is warranted.
Thirdly, most reviews based their risk of bias assess-
ment on a singular risk of bias assessment despite in-
cluding more than one outcome and several reviews
(mostly updates) merged “blinding of participants and
personnel” and “blinding of outcome assessor” into a
single blinding bias domain. The latter was recom-
mended in the 2008 version of the tool, but not in the
updated 2011 version [18]. Hopefully, the merging of
blinding associated bias domains will be addressed when
the reviews in question are updated (again).
Fourthly, risk of bias is very often assessed based on
incomplete or missing information. The judgement of at
least one risk of bias domain as “unclear” was found in
1103 of 1242 included randomized clinical trials (89 %).
Though “unclear” may be a reasonable option in some
trials, this large proportion is a considerable problem. In
many cases, the uncertainty can be resolved by contact-
ing trial authors (who are often able to provide the infor-
mation) or by searching publicly available trial registers.
Table 6 Use of additional non-standard domains and the “other bias” domain in the Cochrane and non-Cochrane reviews that
applied the Cochrane risk of bias tool for randomized clinical trials
Use of additional domains and “other bias” 100 Cochrane reviews (100 %) 31 non-Cochrane reviews (100 %)c P value*
Additional domains
Any additional domain(s) 11 (11 %) 6 (19 %) 0.37
-Adds “baseline imbalance” 6 of 11 (55 %) 2 of 6 (33 %) 1.00
-Adds “funding” or “conflicts of interest” 5 of 11 (45 %) 1 of 6 (17 %) 0.62
-Adds “intention to treat” 2 of 11 (18 %) 2 of 6 (33 %) 0.62
-Adds “compliance” 2 of 11 (18 %) 1 of 6 (17 %) 1.00
-Adds “follow up” 3 of 11 (27 %) 2 of 6 (33 %) 1.00
-Adds “timing of outcome assessment” 2 of 11 (18 %) 1 of 6 (17 %) 1.00
-Adds “overall risk of bias” 1 of 11 (9 %) 4 of 6 (67 %) 0.14
-Adds other additional domaina 6 of 11 (55 %) 2 of 6 (33 %) 1.00
Other biasb
Includes the “other bias” domain 73 (73 %) 17 (55 %) 0.41
-Used for “baseline imbalance” 33 of 73 (45 %) 0 of 17 (0 %) 0.0059
-Used for “funding” or “conflicts of interest” 23 of 73 (32 %) 2 of 17 (12 %) 0.24
-Used for “intervention differed between groups” 16 of 73 (22 %) 0 of 17 (0 %) 0.069
-Used for “unclear reporting by trial publication author” 15 of 73 (21 %) 0 of 17 (0 %) 0.12
-Used for “trial design” 11 of 73 (15 %) 0 of 17 (0 %) 0.20
*P values were calculated with Fisher’s two-tailed exact test
aAll of the following other additional domains appeared ones in review samples: Cochrane reviews: “co-interventions avoided or similar,” “confounding variables,”
“definition of incomplete response,” “definition of local recurrence,” “method of follow up” and “size”; non-Cochrane reviews: “co-intervention” and “double blinding”
b“Other bias”—comments were interpreted and categorised (e.g. the “other bias” comment “There were baseline differences between groups.” was categorised as
“baseline imbalance”). The five most used “other bias”—categories are listed
c31 of 100 non-Cochrane reviews used the Cochrane risk of bias tool for randomized clinical trials (i.e. the tool) and were compared to the 100 Cochrane reviews
that used the tool for randomized clinical trials
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Occasionally, one may access trial protocols, internal
company study reports or reports by drug regulation
agencies (such as the United States’ Food & Drug
Administration) to facilitate better risk of bias judge-
ments [19]. Improved guidelines on how to access
and acquire the relevant information for assessing
risk of bias are warranted.
Furthermore, low inter-rater agreement rates for risk
of bias assessors are a potential problem for users of sys-
tematic reviews. Readers may consider whether a re-
view’s conclusion would have been different if other
reviewers had assessed the risk of bias in the included
trials. It is prudent to check the risk of bias assessments
in a review. Fortunately, the tool has a configuration that
facilitates such checking. Studies assessing between-rater
agreement for complex assessment procedures often
have modest agreement rates [20], which in some cases
may be improved with training [21]. The Cochrane tool
is no exception. Disagreement seems to occur when ter-
minology is used inconsistently (e.g. for blinding [22]),
when judgements are based on insufficient information
or when the intervention is more complex (e.g. in non-
pharmacological trials [9]). In addition, reviewers often
encounter problems when assessing the domains “in-
complete outcome data” and “selective outcome report-
ing” [8]. Clarified terminology, revised structure, better
training options and guidance will hopefully improve
agreement rates. It will be interesting to read the result
of a forthcoming study on the impact of training [23].
Funding/conflicts of interest is also a challenge for the
tool. It is widely believed that industry funding and other
conflicts of interest are associated with higher estimates
of treatment effects in randomized trials [24]. It is more
controversial whether this association is appropriately
accounted for by adding “funding/conflicts of interest”
as an independent bias domain. Adding a domain would
go against the logic structure of the tool, which is based
on core bias domains that reflect fundamental, inde-
pendent bias mechanisms. An alternative option would
be to address the issue within the existing bias domains
(for example, under risk of selective outcome reporting),
while paying careful attention to any clinical or meth-
odological differences between industry funded and non-
funded trials, such as selection of control groups. The
problem with the latter option is that detailed informa-
tion on trial conduct is often missing. It is notable that
5 % of Cochrane reviews added funding as a separate
domain and that 32 % incorporated funding into the
“other bias” function. Clearly, more work is needed on
this issue.
A general tension exists between bias in randomized tri-
als as defined mechanistically in the tool, and as defined
empirically based on results from meta-epidemiological
studies. Several design features of randomized clinical
trials have been reported in meta-epidemiological studies
to be associated with exaggerated treatment effects, such
as sample size [25], development country status [26], sin-
gle centre status [27] and stopping a trial early [28]. The
list of potential bias domains selected purely on empirical
grounds will quickly become quite large and involve a risk
of spurious inclusion of bias domains that are secondary
in nature (and thus, in principle, explainable by the core
bias domains). However, an open question is whether a
pragmatic and careful selection of a few empirically
defined bias domains that are simple to assess (such as
sample size or single centre status) may act as proxy mea-
sures and supplement a risk of bias tool based on mechan-
istically defined core bias domains.
Conclusions
Based on published comments, the Cochrane tool for
assessing risk of bias in randomized clinical trials is
regarded as an important step forward but challenged by
how to deal with the risk of bias associated with fund-
ing/conflicts of interest and modest inter-rater agree-
ment. The tool is used in a very high proportion of
Cochrane reviews and in many non-Cochrane reviews,
but often in a non-recommended way, for example, by
incorporating additional bias domains. The tool has
become the standard approach to assess risk of bias in
randomized clinical trials. Its implementation may be
further improved by a revised structure, further research
and more focused guidance.
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